Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival

doi:10.3748/wjg.v21.i21.6621

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 21

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10224)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

532

WORD

323

HTML

3800

Figures (1-3)

461

Tables (1-2)

473

Sum=5589

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1575

Download

3051

Sum=4626

Jun 7, 2015 (publication date) through Feb 21, 2026

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Cohort Study

World J Gastroenterol. Jun 7, 2015; 21(21): 6621-6630
Published online Jun 7, 2015. doi: 10.3748/wjg.v21.i21.6621

Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival

Hui-Lin Ye, Dou-Dou Li, Qing Lin, Yu Zhou, Quan-Bo Zhou, Bing Zeng, Zhi-Qiang Fu, Wen-Chao Gao, Yi-Min Liu, Rui-Wan Chen, Zhi-Hua Li, Ru-Fu Chen

Hui-Lin Ye, Qing Lin, Yu Zhou, Quan-Bo Zhou, Bing Zeng, Zhi-Qiang Fu, Wen-Chao Gao, Ru-Fu Chen, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China

Dou-Dou Li, Yi-Min Liu, Department of Radiotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China

Rui-Wan Chen, Department of Radiotherapy, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China

Zhi-Hua Li, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China

Author contributions: Ye HL and Li DD contributed equally to this study; Ye HL and Lin Q performed the majority of experiments; Li DD conducted part of the experiment and revised the paper; Li ZH and Chen RF conceived the experiments, analyzed and interpreted data and wrote the manuscript; Zhou Y, Zhou QB, Zeng B, Fu ZQ, Gao WC, Liu YM and Chen RW participated in the experiment and helped analyze the data; all authors read and approved the final manuscript.

Ethics approval: The study was reviewed and approved by the Institutional Review Board of Sun Yat-sen Memorial hospital and the Ethics Committee of Sun Yat-sen Memorial Hospital.

Informed consent: All study participants provided informed written consent prior to study enrollment.

Conflict-of-interest: The authors disclose no conflicts of interest.

Data sharing: The technical appendix, statistical code, and dataset are available from the corresponding author at chenrf_sysu@163.com. Consent was not obtained but the presented data are anonymized and the risk of identification is low.

Correspondence to: Dr. Ru-Fu Chen, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yan-Jiang Xi Road, Guangzhou 510120, Guangdong Province, China. chenrf_sysu@163.com

Telephone: +86-21-81332020 Fax: +86-21-81332020

Received: November 29, 2014
Peer-review started: November 29, 2014
First decision: December 26, 2014
Revised: January 24, 2015
Accepted: February 13, 2015
Article in press: February 13, 2015
Published online: June 7, 2015
Processing time: 193 Days and 22.7 Hours

Abstract

AIM: To analyze RASSF6 expression in pancreatic ductal adenocarcinoma (PDAC) and to determine whether RASSF6 has an independent prognostic value in PDAC.

METHODS: We studied RASSF6 expression in 96 histologically confirmed PDAC samples and 20 chronic pancreatitis specimens using immunohistochemistry and real-time quantitative reverse transcription-PCR. PDAC issues were then classified as RASSF6 strongly positive, weakly positive or negative. RASSF6 mRNA and protein expression in PDAC samples with strong positive staining was further evaluated using real-time PCR and Western blot analysis. Lastly, correlations between RASSF6 staining and patients’ clinicopathological variables and outcomes were assessed.

RESULTS: RASSF6 was negatively expressed in 51 (53.1%) PDAC samples, weakly positively expressed in 29 (30.2%) and strongly positively expressed in 16 (16.7%), while its expression was much higher in para-tumor tissues and chronic pancreatitis tissues. Positive relationships between RASSF6 expression and T-stage (P = 0.047) and perineural invasion (P = 0.026) were observed. The median survival time of strongly and weakly positive and negative RASSF6 staining groups was 33 mo, 15 mo and 11 mo, respectively. Cox multivariate analysis indicated that RASSF6 was an independent prognostic indicator of overall survival in patients with PDAC. A survival curve analysis revealed that increased RASSF6 expression was correlated with better overall survival (P = 0.009).

CONCLUSION: RASSF6 expression is an independent biomarker of an unfavorable prognosis in patients with PDAC.

Keywords: Pancreatic cancer; Pancreatic ductal adenocarcinoma; Prognostic marker; RASSF6; K-ras; Immunohistochemistry; Survival analysis

Core tip: This is the first study that provides evidence for the prognostic value and potential tumor suppressor activity of RASSF6 in pancreatic ductal adenocarcinoma. The prominent findings in this study are that RASSF6 is an independent prognostic marker for predicting the survival of pancreatic ductal adenocarcinoma patients after curative operations and that the expression of RASSF6 might decrease with the development of cancer.